BioTuesdays

HCW starts Tobira Therapeutics at buy

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday.Tobira is focused on the development of a sole drug candidate...

HCW starts BioPharmX at buy

H.C. Wainwright has initiated coverage of BioPharmX (NYSE MKT:BPMX) with a “buy” rating and $3 price target. The stock closed at 99 cents on Wednesday.BioPharmX’s lead product is Violet for the treatment of fibrocystic...

Canaccord downgrades AngioDynamics to hold

Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten...

Oramed completes Phase 2b oral insulin study

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed.The double-blind, randomized Phase 2b study of 180 patients with Type...

Stifel upgrades Exelixis to buy

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.Exelixis is developing small molecule therapies for the treatment of cancer and is focusing...

BTIG starts OraSure Technologies at buy

BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday.“A profitable small-cap diagnostics company is a rare find,” writes...

Subscribe

Sign up to our weekly BioTuesdays newsletter.